New entrants are hesitant to get into dealing with cannabinoids because of the marketing hurdles that they will have to face as well as the regulatory and marketing challenges that are presented. Many companies that are in the field are relaying on the cannabis plant as an entry point for their R&D efforts. Many have taken the path of what they consider to be next generation drug development. They do this in hopes of overcoming their concerns.
Key Takeaways:
- Everyone is using THC or CBD in an effective way for the body. The problem is that when extracted from the plant, there is very little of the substance and can be very expensive to isolate them.
- It is very difficult for doctors to prescribe the correct amount if the marijuana is in joint form. Everyone will be inhaling a different amount and it cannot be exact.
- Cannabinoid based medicines are becoming more accepted by the medical community. Once the stigma of what the medicine is dissipates, the more accepting the community will be to use.
“The study also showed the formation of THC metabolites were reduced, and AP-CBD/THC was found to be safe and well-tolerated, with no serious adverse events reported.”
Read more: http://www.bioworld.com/content/can-cannabinoids-earn-respect-new-candidates-not-just-blowing-smoke